Alterity Therapeutics Ltd. (AU:ATH)
ASX:ATH
ATH Stock Chart & Stats
AU$0.01
>-AU$0.01(-10.00%)
At close: 4:00 PM EST
AU$0.01
>-AU$0.01(-10.00%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.02
Previous CloseN/A
Volume25.42M
Average Volume (3M)16.33M
Market Cap
AU$76.13M
Enterprise ValueAU$37.97M
Total Cash (Recent Filing)AU$49.20M
Total Debt (Recent Filing)AU$163.91K
Price to Earnings (P/E)―
Beta1.93
Next Earnings
Mar 04, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding10,875,416,000
10 Day Avg. Volume24,202,939
30 Day Avg. Volume16,327,471
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.51
Price to Sales (P/S)11.76
P/FCF Ratio-5.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$2.26M
Bulls Say, Bears Say
Bulls Say
Very Low Leverage / Minimal DebtA very low debt-to-equity ratio gives Alterity durable financial flexibility: lower fixed interest obligations reduce bankruptcy risk, preserve runway for clinical programs, and make it easier to prioritize R&D or strategic partnerships without debt servicing constraints.
Robust Top-line GrowthSustained revenue growth at ~46% indicates improving funding inflows or commercial activity relative to peers for a clinical-stage biotech. Over 2-6 months this trend supports stronger institutional interest, underpins continued investment in trials, and strengthens partner negotiations.
Focused Clinical-stage Pipeline In NeurodegenerationA concentrated pipeline targeting neurodegenerative diseases creates structural expertise and clear strategic focus. This specialization can attract partner interest, concentrated R&D efficiencies, and high-value outcomes if clinical milestones succeed, improving long-term optionality.
Bears Say
Persistent Negative Profitability And MarginsRecurring negative margins reflect the company's inability to convert revenue into operating profits. Over the medium term this depletes equity, weakens return metrics, and forces reliance on external funding unless operational efficiencies or successful program de-risking materially improve profitability.
Negative Operating And Free Cash FlowConsistent cash burn and worsening free cash flow growth reduce runway and increase the probability of dilutive financing. This constrains strategic flexibility, may delay programs if funding gaps emerge, and creates execution risk for clinical timelines absent non-dilutive funding or partnerships.
Dependence On Equity Financing And No Commercial RevenueReliance on external capital issuance and milestone-based partner payments is a structural vulnerability. Market conditions or financing cycles can delay access to funds, cause dilution, and threaten program continuity, especially if clinical milestones fall short or fundraising windows narrow.
Alterity Therapeutics News
ATH FAQ
What was Alterity Therapeutics Ltd.’s price range in the past 12 months?
Alterity Therapeutics Ltd. lowest share price was <AU$0.01 and its highest was AU$0.02 in the past 12 months.
What is Alterity Therapeutics Ltd.’s market cap?
Alterity Therapeutics Ltd.’s market cap is AU$76.13M.
When is Alterity Therapeutics Ltd.’s upcoming earnings report date?
Alterity Therapeutics Ltd.’s upcoming earnings report date is Mar 04, 2027 which is in 341 days.
How were Alterity Therapeutics Ltd.’s earnings last quarter?
Alterity Therapeutics Ltd. released its earnings results on Feb 25, 2026. The company reported AU$0 earnings per share for the quarter, the consensus estimate of AU$0 by AU$0.
Is Alterity Therapeutics Ltd. overvalued?
According to Wall Street analysts Alterity Therapeutics Ltd.’s price is currently Overvalued.
Does Alterity Therapeutics Ltd. pay dividends?
Alterity Therapeutics Ltd. does not currently pay dividends.
What is Alterity Therapeutics Ltd.’s EPS estimate?
Alterity Therapeutics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Alterity Therapeutics Ltd. have?
Alterity Therapeutics Ltd. has 10,875,416,000 shares outstanding.
What happened to Alterity Therapeutics Ltd.’s price movement after its last earnings report?
Alterity Therapeutics Ltd. reported an EPS of AU$0 in its last earnings report, expectations of AU$0. Following the earnings report the stock price went down -9.091%.
Which hedge fund is a major shareholder of Alterity Therapeutics Ltd.?
Currently, no hedge funds are holding shares in AU:ATH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alterity Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:ATH Sentiment 70%
Sector Average ―
Sector Average ―
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Fundamentals
Return on Equity
-30.19%
Trailing 12-Months
Asset Growth
481.25%
Trailing 12-Months
Company Description
Alterity Therapeutics Ltd.
Alterity Therapeutics (ATH) is a biotechnology company focused on developing innovative therapeutics for neurodegenerative diseases, primarily targeting conditions such as Parkinson's disease and Alzheimer's disease. The company leverages its proprietary drug discovery platform to identify and develop small molecule therapies aimed at modifying disease progression and improving patient outcomes. Alterity is dedicated to advancing its clinical programs and expanding its pipeline of novel treatments to address significant unmet medical needs in the neurology sector.
Technical Analysis
Imugene
―
Paradigm Biopharmaceuticals
―
EZZ Life Science Holdings Ltd.
―
Recce Pharmaceuticals Ltd.
―
Arovella Therapeutics Limited
―
Options Prices
Currently, No data available
---